Source | Evidence on protein | Close homologs |
---|---|---|
Cuervo et al. | no | yes: 0 |
Hassani et al. | no | yes: 0 |
Forrest at al. (metacyclic) | no | yes: 0 |
Forrest at al. (procyclic) | no | yes: 0 |
Silverman et al. | no | yes: 0 |
Pissara et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Pires et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Silverman et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Jamdhade et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
DeepLoc | ||
SignalP6 | no | yes: 0, no: 21 |
NetGPI | no | yes: 0, no: 21 |
Term | Name | Level | Count |
---|---|---|---|
GO:0005813 | centrosome | 3 | 2 |
GO:0005815 | microtubule organizing center | 2 | 2 |
GO:0005929 | cilium | 4 | 1 |
GO:0005930 | axoneme | 2 | 2 |
GO:0042995 | cell projection | 2 | 1 |
GO:0043226 | organelle | 2 | 1 |
GO:0043227 | membrane-bounded organelle | 3 | 1 |
GO:0110165 | cellular anatomical entity | 1 | 2 |
GO:0120025 | plasma membrane bounded cell projection | 3 | 1 |
Related structures:
AlphaFold database: A4HB17
Term | Name | Level | Count |
---|---|---|---|
GO:0006793 | phosphorus metabolic process | 3 | 16 |
GO:0006796 | phosphate-containing compound metabolic process | 4 | 16 |
GO:0008152 | metabolic process | 1 | 16 |
GO:0009987 | cellular process | 1 | 16 |
GO:0016310 | phosphorylation | 5 | 16 |
GO:0044237 | cellular metabolic process | 2 | 16 |
Term | Name | Level | Count |
---|---|---|---|
GO:0003824 | catalytic activity | 1 | 16 |
GO:0016301 | kinase activity | 4 | 16 |
GO:0016740 | transferase activity | 2 | 16 |
GO:0016772 | transferase activity, transferring phosphorus-containing groups | 3 | 16 |
GO:0004550 | nucleoside diphosphate kinase activity | 5 | 9 |
GO:0016776 | phosphotransferase activity, phosphate group as acceptor | 4 | 9 |
GO:0019205 | nucleobase-containing compound kinase activity | 5 | 9 |
Leishmania | From | To | Domain/Motif | Score |
---|---|---|---|---|
CLV_C14_Caspase3-7 | 176 | 180 | PF00656 | 0.459 |
CLV_C14_Caspase3-7 | 53 | 57 | PF00656 | 0.259 |
CLV_PCSK_KEX2_1 | 51 | 53 | PF00082 | 0.377 |
CLV_PCSK_PC1ET2_1 | 51 | 53 | PF00082 | 0.397 |
CLV_PCSK_PC7_1 | 47 | 53 | PF00082 | 0.415 |
CLV_PCSK_SKI1_1 | 256 | 260 | PF00082 | 0.212 |
CLV_PCSK_SKI1_1 | 338 | 342 | PF00082 | 0.305 |
CLV_PCSK_SKI1_1 | 9 | 13 | PF00082 | 0.327 |
DEG_APCC_DBOX_1 | 255 | 263 | PF00400 | 0.507 |
DEG_SPOP_SBC_1 | 57 | 61 | PF00917 | 0.266 |
DOC_MAPK_gen_1 | 191 | 200 | PF00069 | 0.409 |
DOC_MAPK_RevD_3 | 38 | 52 | PF00069 | 0.492 |
DOC_PP4_FxxP_1 | 139 | 142 | PF00568 | 0.317 |
DOC_PP4_FxxP_1 | 201 | 204 | PF00568 | 0.384 |
DOC_PP4_FxxP_1 | 251 | 254 | PF00568 | 0.439 |
DOC_PP4_FxxP_1 | 71 | 74 | PF00568 | 0.467 |
DOC_SPAK_OSR1_1 | 120 | 124 | PF12202 | 0.359 |
DOC_USP7_MATH_1 | 104 | 108 | PF00917 | 0.468 |
DOC_USP7_MATH_1 | 204 | 208 | PF00917 | 0.317 |
DOC_USP7_MATH_1 | 254 | 258 | PF00917 | 0.550 |
DOC_USP7_MATH_1 | 58 | 62 | PF00917 | 0.408 |
DOC_USP7_MATH_1 | 90 | 94 | PF00917 | 0.411 |
DOC_USP7_UBL2_3 | 305 | 309 | PF12436 | 0.522 |
LIG_14-3-3_CanoR_1 | 63 | 69 | PF00244 | 0.467 |
LIG_Actin_WH2_2 | 36 | 53 | PF00022 | 0.431 |
LIG_APCC_ABBA_1 | 129 | 134 | PF00400 | 0.358 |
LIG_APCC_ABBA_1 | 198 | 203 | PF00400 | 0.287 |
LIG_BIR_II_1 | 1 | 5 | PF00653 | 0.456 |
LIG_FHA_1 | 1 | 7 | PF00498 | 0.617 |
LIG_FHA_1 | 146 | 152 | PF00498 | 0.333 |
LIG_FHA_1 | 193 | 199 | PF00498 | 0.460 |
LIG_FHA_1 | 35 | 41 | PF00498 | 0.401 |
LIG_FHA_1 | 65 | 71 | PF00498 | 0.385 |
LIG_FHA_1 | 83 | 89 | PF00498 | 0.301 |
LIG_FHA_1 | 94 | 100 | PF00498 | 0.327 |
LIG_FHA_2 | 122 | 128 | PF00498 | 0.380 |
LIG_FHA_2 | 174 | 180 | PF00498 | 0.452 |
LIG_FHA_2 | 281 | 287 | PF00498 | 0.475 |
LIG_FHA_2 | 51 | 57 | PF00498 | 0.336 |
LIG_LIR_Apic_2 | 137 | 142 | PF02991 | 0.440 |
LIG_LIR_Apic_2 | 250 | 254 | PF02991 | 0.442 |
LIG_LIR_Gen_1 | 102 | 113 | PF02991 | 0.344 |
LIG_LIR_Gen_1 | 162 | 172 | PF02991 | 0.444 |
LIG_LIR_Gen_1 | 236 | 246 | PF02991 | 0.467 |
LIG_LIR_LC3C_4 | 148 | 152 | PF02991 | 0.185 |
LIG_LIR_Nem_3 | 102 | 108 | PF02991 | 0.392 |
LIG_LIR_Nem_3 | 162 | 168 | PF02991 | 0.430 |
LIG_LIR_Nem_3 | 236 | 241 | PF02991 | 0.467 |
LIG_LIR_Nem_3 | 253 | 258 | PF02991 | 0.453 |
LIG_LIR_Nem_3 | 267 | 272 | PF02991 | 0.470 |
LIG_MYND_3 | 259 | 263 | PF01753 | 0.413 |
LIG_NRBOX | 224 | 230 | PF00104 | 0.402 |
LIG_REV1ctd_RIR_1 | 337 | 343 | PF16727 | 0.363 |
LIG_SH2_CRK | 255 | 259 | PF00017 | 0.433 |
LIG_SH2_CRK | 298 | 302 | PF00017 | 0.522 |
LIG_SH2_GRB2like | 33 | 36 | PF00017 | 0.243 |
LIG_SH2_SRC | 33 | 36 | PF00017 | 0.289 |
LIG_SH2_STAP1 | 298 | 302 | PF00017 | 0.522 |
LIG_SH2_STAP1 | 336 | 340 | PF00017 | 0.433 |
LIG_SH2_STAT5 | 111 | 114 | PF00017 | 0.342 |
LIG_SH2_STAT5 | 31 | 34 | PF00017 | 0.382 |
LIG_SH2_STAT5 | 49 | 52 | PF00017 | 0.332 |
LIG_SH3_3 | 16 | 22 | PF00018 | 0.562 |
LIG_SH3_3 | 207 | 213 | PF00018 | 0.427 |
LIG_SH3_3 | 291 | 297 | PF00018 | 0.406 |
LIG_SH3_3 | 52 | 58 | PF00018 | 0.360 |
LIG_SUMO_SIM_anti_2 | 148 | 154 | PF11976 | 0.445 |
LIG_SUMO_SIM_anti_2 | 206 | 212 | PF11976 | 0.435 |
LIG_SUMO_SIM_anti_2 | 282 | 289 | PF11976 | 0.426 |
LIG_SUMO_SIM_anti_2 | 37 | 42 | PF11976 | 0.467 |
LIG_SUMO_SIM_par_1 | 150 | 156 | PF11976 | 0.447 |
LIG_SUMO_SIM_par_1 | 277 | 283 | PF11976 | 0.432 |
LIG_SUMO_SIM_par_1 | 36 | 42 | PF11976 | 0.450 |
LIG_SUMO_SIM_par_1 | 93 | 103 | PF11976 | 0.411 |
LIG_WRC_WIRS_1 | 266 | 271 | PF05994 | 0.381 |
MOD_CK1_1 | 280 | 286 | PF00069 | 0.512 |
MOD_CK1_1 | 93 | 99 | PF00069 | 0.363 |
MOD_CK2_1 | 121 | 127 | PF00069 | 0.432 |
MOD_GlcNHglycan | 136 | 139 | PF01048 | 0.455 |
MOD_GlcNHglycan | 216 | 219 | PF01048 | 0.291 |
MOD_GlcNHglycan | 222 | 225 | PF01048 | 0.284 |
MOD_GlcNHglycan | 244 | 247 | PF01048 | 0.273 |
MOD_GlcNHglycan | 44 | 47 | PF01048 | 0.480 |
MOD_GSK3_1 | 233 | 240 | PF00069 | 0.485 |
MOD_GSK3_1 | 90 | 97 | PF00069 | 0.464 |
MOD_N-GLC_1 | 204 | 209 | PF02516 | 0.293 |
MOD_N-GLC_1 | 34 | 39 | PF02516 | 0.389 |
MOD_NEK2_1 | 1 | 6 | PF00069 | 0.462 |
MOD_NEK2_1 | 121 | 126 | PF00069 | 0.333 |
MOD_NEK2_1 | 145 | 150 | PF00069 | 0.348 |
MOD_NEK2_1 | 262 | 267 | PF00069 | 0.454 |
MOD_NEK2_1 | 50 | 55 | PF00069 | 0.378 |
MOD_NEK2_2 | 58 | 63 | PF00069 | 0.367 |
MOD_PKA_2 | 119 | 125 | PF00069 | 0.357 |
MOD_Plk_1 | 204 | 210 | PF00069 | 0.278 |
MOD_Plk_1 | 93 | 99 | PF00069 | 0.366 |
MOD_Plk_2-3 | 34 | 40 | PF00069 | 0.367 |
MOD_Plk_4 | 204 | 210 | PF00069 | 0.278 |
MOD_Plk_4 | 265 | 271 | PF00069 | 0.496 |
MOD_Plk_4 | 297 | 303 | PF00069 | 0.506 |
MOD_Plk_4 | 64 | 70 | PF00069 | 0.361 |
MOD_Plk_4 | 72 | 78 | PF00069 | 0.336 |
MOD_Plk_4 | 94 | 100 | PF00069 | 0.324 |
TRG_ENDOCYTIC_2 | 111 | 114 | PF00928 | 0.354 |
TRG_ENDOCYTIC_2 | 255 | 258 | PF00928 | 0.427 |
TRG_ENDOCYTIC_2 | 298 | 301 | PF00928 | 0.522 |
TRG_ENDOCYTIC_2 | 336 | 339 | PF00928 | 0.447 |
TRG_ER_diArg_1 | 311 | 314 | PF00400 | 0.451 |
TRG_Pf-PMV_PEXEL_1 | 86 | 91 | PF00026 | 0.417 |
Protein | Taxonomy | Sequence identity | Coverage |
---|---|---|---|
A0A0N1IJQ8 | Leptomonas seymouri | 71% | 100% |
A0A0N1PC23 | Leptomonas seymouri | 30% | 100% |
A0A0S4IXH2 | Bodo saltans | 30% | 100% |
A0A1X0P5C0 | Trypanosomatidae | 32% | 100% |
A0A1X0PAT4 | Trypanosomatidae | 45% | 98% |
A0A3Q8IJQ8 | Leishmania donovani | 29% | 100% |
A0A3R7M6K1 | Trypanosoma rangeli | 46% | 99% |
A0A3R7N390 | Trypanosoma rangeli | 31% | 100% |
A0A3S7X855 | Leishmania donovani | 84% | 100% |
A4HN58 | Leishmania braziliensis | 29% | 100% |
A4IA74 | Leishmania infantum | 84% | 100% |
A4IBS5 | Leishmania infantum | 29% | 100% |
C9ZM33 | Trypanosoma brucei gambiense (strain MHOM/CI/86/DAL972) | 44% | 98% |
C9ZYU7 | Trypanosoma brucei gambiense (strain MHOM/CI/86/DAL972) | 32% | 100% |
E9AFL1 | Leishmania major | 29% | 100% |
E9B587 | Leishmania mexicana (strain MHOM/GT/2001/U1103) | 82% | 100% |
E9B6R5 | Leishmania mexicana (strain MHOM/GT/2001/U1103) | 30% | 100% |
Q4Q2P6 | Leishmania major | 82% | 100% |
Q5E9Y9 | Bos taurus | 25% | 91% |
Q9QXL7 | Rattus norvegicus | 26% | 87% |
Q9QXL8 | Mus musculus | 25% | 87% |
Q9Y5B8 | Homo sapiens | 25% | 91% |
V5BXY9 | Trypanosoma cruzi | 30% | 99% |
V5DLW4 | Trypanosoma cruzi | 44% | 98% |